Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Abstract: Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells. The first-generation HMA azacitidine and decitabine have now been in standard clinical use for some time, offering a valuable alternative to previous treatments in acute myeloid leukemia and myelodysplastic syndromes, so far particularly in older, medically non-fit patients. However, the longer we use these drugs, the more we are confronted with the (almost inevitable) development of resistance. This review provides insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and HMA-based combination therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Leukemia. - 35 (2021) , 1873–1889, ISSN: 1476-5551
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2021
- Creator
- DOI
-
10.1038/s41375-021-01218-0
- URN
-
urn:nbn:de:bsz:25-freidok-2186309
- Rights
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:46 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Stomper, Julia
- Rotondo, John Charles
- Greve, Gabriele
- Lübbert, Michael
- Universität
Time of origin
- 2021
Other Objects (12)
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study
Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study
Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study
Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes